A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy

Transfusion and Apheresis Science

Volumn 43, Issue 3, 2010, Pages 321-326

  Simona, Bassi ^a   Cristina, Rabascio ^a   Luca, Nassi ^a   Sara, Steffanoni ^a   Aleksandra, Babic ^a   Paola, Bertazzoni ^a   Federica, Gigli ^a   Pierluigi, Antoniotti ^a   Laura, Orlando ^a   Simona, Sammassimo ^a   Jessica, Quarna ^a   Mara, Negri ^a   Giovanni, Martinelli ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; CYTARABINE; ETOPOSIDE; MELPHALAN; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE PAIN; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ENGRAFTMENT; FEMALE; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LEUKAPHERESIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; STEM CELL MOBILIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FILGRASTIM; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 78649460876     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2010.10.001     Document Type: Article

References (18)

1. Vose J.M., Zhang M.J., Rowlings P.A., Lazarus H.M., Bolwell B.J., Freytes C.O., et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001, 19:406-413.
2. Philip T., Guglielmi C., Hagenbeek A., Somers R., Van der Lelie H., Bron D., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
3. Yuen A.R., Rosenberg S.A., Hoppe R.T., Halpern J.D., Horning J.S. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997, 89:814-822.
4. To B.L., Haylock D.N., Simmons P.J., Juttner C.A. The biology and clinical uses of blood stem cells. Blood 1997, 89:2233-2258.
5. Ozer H., Armitage J.O., Bennett C.L., Crawford J., Demetri G.D., Pizzo P.A., et al. 2000 Update of recommandations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practise guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000, 18:3558-3585.
6. Curran M.P., Goa K.L. Pegfilgrastim. Drugs 2002, 62:1207-1213.
7. Zamboni W.C. Pharmacokinetics of pegfilgrastim. Pharmacotherapy 2003, 23:9-14.
8. Kroschinsky F., Holig K., Ehninger G. The role of pegfilgrastim in mobilization of hematopoietic stem cells. Transfus Apher Sci 2008, 38:237-244.
9. Velasquez W.S., McLaughlin P., Tucker S., Hagemeister F.B., Swan F., Rodriguez M.A., et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994, 12:1169-1176.
10. Sutherland D.R., Anderson L., Keeney M., Nayar R., The Chin.-Yee.I., GE I.S.H.A. Guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graf Engineering. J Hematother 1996, 5:213-226.
11. Holmes F.A., O'Shaughnessy J.A., Vukelja S., Jones S.E., Shogan J., Savin M., et al. Blinded, randomized, multicenter study to evaluated single administration pegfilgrastim once per cycle versus daily Filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002, 20:727-731.
12. Vose J.M., Crump M., Lazarus H., Emmanouilides C., Schenkein D., Moore J., et al. Randomized, multicenter open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003, 21(3):514-519.
13. Russell N., Mesters R., Schubert J., Boogaerts M., Johnsen H.E., Canizo C.D., et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008, 93:405-412.
14. Isidori A., Tani M., Bonifazi F., Zinzani P., Curti A., Motta M.R., et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilie stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005, 90:225-231.
15. Nosari A., Cairoli R., Ciapanna D., Gargantini L., Intropido L., Baraté C., et al. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. Bone Marrow Transplant 2006, 38:413-416.
16. Bruns I., Steidl U., Fischer J.C., Czibere A., Kobbe G., Raschke S., et al. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica 2008, 93:347-355.
17. Tricot G., Barlogie B., Zangari M., van Rhee F., Hoering A., Szymonifka J., et al. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematological 2008, 93:1739-1742.
18. Lee J.L., Kim S., Kim S.W., Kim E.K., Kim S.B., Kang Y.K., et al. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin lymphoma: comparison with high dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 2005, 35:449-454.